Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to empower research & development (R&D) of novel ADC with AI based on their technological strengths in R&D of ADC and AI, respectively.

Mabwell has excellent capabilities in ADC technology platform construction and mAb/bsAb drug discovery, and has established the entire industrial chain from R&D to production of ADCs. Based on its comprehensive platform technology and rich R&D data accumulation, Mabwell has developed multiple novel ADCs with high structural homogeneity and stable quality, which have been clinically validated. As a pioneer in generative AI-driven drug discovery and development, InSilicon has built Pharma.AI, an integrated drug discovery and development platform that covers biology, chemistry, clinical medicine and scientific research, with engines such as PandaOmics and Generative Biologics under the Biology segment, which improves R&D efficiency by empowering drug target identification and generating molecular fragments from scratch. According to the collaboration agreement, both parties will combine their respective platform advantages to develop new generation payloads with new biological mechanisms, innovative structures and pharmacological activities, to enhance the efficiency of innovation of ADC, and to further refine and iterate the AI platform.

Dr. Datao Liu, Chairman of the Board, CEO of Mabwell, said, "We are excited to collaborate with Insilico. Artificial intelligence has shown transformative potential in the biomedical field. Mabwell has deep expertise in the field of ADC and embraces cutting-edge technologies actively, while Insilicon Intelligence has developed advanced AI platforms. We believe that the cooperation can combine the strengths of both companies to further enhance the efficiency of drug discovery and development, empowering original innovation, providing more therapeutic choices for patients, and meeting the unmet clinical needs around the world."

"I am delighted to announce our collaboration with Mabwell, which aligns with our broader focus on biologics," said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. "Antibody-drug conjugates represent a promising new modality that leverages emeraging technologies to address challenging diseases. Similarly, generative AI offers transformative potential to accelerate the pace of innovation. By combining Mabwell's deep expertise in biologics with Insilico's advanced generative AI-driven platforms, we aim to develop next-generation therapies that address unmet medical needs with unparalleled efficiency and precision."

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com